Clinical Outcomes and Donor-specific Antibody Rebound 5 y After Kidney Transplant Enabled by Imlifidase Desensitization
Five-year outcomes of imlifidase-enabled incompatible transplants are overall favorable. DSA rebound is common, but antibody strength lessens in the long term, and longitudinally persisting DSAs did not lead to premature graft failure.
Authors
- Elaina Weldon
- Ian Jaffe (ORCID: https://orcid.org/0000-0002-7309-308X)
- Robert A. Montgomery (ORCID: https://orcid.org/0000-0003-2728-4552)
- Vasishta Tatapudi (ORCID: https://orcid.org/0000-0002-2717-3628)
- Rebecca Dieter (ORCID: https://orcid.org/0000-0001-7906-1372)
- Massimo Mangiola (ORCID: https://orcid.org/0000-0002-5406-4005)
- Anna Runström (ORCID: https://orcid.org/0000-0001-9139-0283)
- Bonnie E. Lonze (ORCID: https://orcid.org/0000-0002-0973-1657)
- Cecilia L. Deterville
Institutions
- Hansa Biopharma (Sweden) (SE)
- New York University (US)
Publication Details
- Journal
- Transplantation Direct
- Published
- 2025-01-09
- DOI
- https://doi.org/10.1097/txd.0000000000001752
- Citations
- 4
- Primary Topic
- Renal Transplantation Outcomes and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 7.94
Funders
- York University
- National Institutes of Health
- NYU Grossman School of Medicine
- National Center for Advancing Translational Sciences